Three Years of Real-World Data Reveal How Well the Cholesterol Gene Silencer Inclisiran Holds Up

When inclisiran was approved, it arrived with an almost futuristic promise: a twice-yearly injection that would silence a gene in the liver and drive down the cholesterol that clogs arteries, freeing patients from the daily discipline of pills. Now, one of the longest real-world follow-ups of the drug has delivered a more nuanced verdict. A three-year analysis from the German Inclisiran Network, published in Clinical Research in Cardiology, shows that the RNA-based therapy achieves meaningful LDL cholesterol reductions in routine clinical practice, but with far greater variability between and within individual patients than the clinical trials suggested, and with roughly one in three patients abandoning the treatment before the study ended.

Inclisiran belongs to a class of drugs called small interfering RNAs, or siRNAs. These are short, chemically synthesized RNA molecules designed to bind to a specific messenger RNA inside cells and trigger its destruction. In the case of inclisiran, the target is the messenger RNA for proprotein convertase subtilisin/kexin type 9, better known as PCSK9, a protein made by the liver that normally marks LDL receptors for degradation. By silencing PCSK9 production, inclisiran allows more LDL receptors to remain on the surface of liver cells, where they can pull LDL cholesterol out of the bloodstream. Because the drug is delivered inside a lipid nanoparticle and taken up by the liver, a subcutaneous injection every six months after an initial loading phase is enough to sustain the effect, a dosing schedule that was expected to solve the adherence problems that plague daily oral medications.

In randomized trials, inclisiran lowered LDL cholesterol by about 50 percent. The new real-world study tells a different story. Researchers led by Umidakhon Makhmudova and Oliver Weingärtner analyzed electronic health records from 109 adults treated at ten specialized lipid clinics across Germany between February 2021 and December 2024, with a median follow-up of 33 months and lipid measurements extending to 39 months. The median LDL cholesterol reduction across all follow-up timepoints was 28 percent, substantially less than the trial figure. Yet when the researchers looked at each patient’s lowest recorded LDL value during follow-up, the median nadir reduction reached 46 percent, close to the trial results. The gap between these two numbers is the study’s central finding: many patients achieved a strong response at some point, but that response was not consistently maintained over time.

The cohort itself explains part of the discrepancy. These were not the carefully selected trial volunteers of the ORION program. Nearly 92 percent were classified as very high cardiovascular risk, 83.5 percent had established atherosclerotic cardiovascular disease, and almost half carried a clinical or genetic diagnosis of familial hypercholesterolemia. Only about 30 percent were taking statins, largely because the majority of patients, roughly 70 percent, were statin-intolerant. Nearly 39 percent had previously been treated with PCSK9 monoclonal antibodies, a group known from other studies to show blunted responses when switched to inclisiran, possibly due to residual antibody effects or differences in how hepatic and extrahepatic PCSK9 are regulated. In this difficult-to-treat population, a 28 percent median reduction is not a failure of the drug so much as a reflection of how resistant some forms of dyslipidemia can be.

The variability data are striking. Individual patients ranged across the full spectrum of response, and the researchers documented significant within-person fluctuations in LDL cholesterol over the three years, occurring even in patients whose background lipid-lowering therapy was never changed. The authors point to several plausible contributors: lifestyle changes, adherence to concomitant medications, and the well-documented natural fluctuation of LDL cholesterol itself, which varies with diet, season, and physiology. The finding carries a practical warning for clinicians, because a single LDL measurement may overstate or understate a patient’s true response, and treatment decisions based on one timepoint risk misclassification. When the researchers defined non-response as a reduction below 25 percent, 43 percent of patients qualified using their overall median, but only 16.5 percent qualified using their nadir values.

Guideline targets proved hard to reach. European recommendations for very high-risk patients call for LDL cholesterol below 1.4 mmol/L, or 55 mg/dL, and a reduction of at least 50 percent from baseline. Over the entire follow-up, 45 percent of patients achieved the target value at least once, 44 percent achieved a 50 percent reduction at least once, and only 33 percent achieved both. More sobering still, the proportions of patients sustaining these achievements at least half the time fell to 24.8 percent, 16.5 percent, and 8.3 percent respectively. The study thus quantifies a persistent treatment gap even under the favorable conditions of specialized lipid clinics, where monitoring is intensive and patients are highly motivated.

Treatment persistence emerged as the other major storyline. Over three years, 28.4 percent of patients discontinued inclisiran, most commonly because of a perceived lack of efficacy, reported in 15.6 percent, followed by adverse effects in 7.3 percent and a combination of both in 1.8 percent. Patients who stopped for lack of efficacy were significantly older, averaging 68.5 years compared with 63.0 years among those who continued, and were less likely to be receiving background lipid-lowering therapy. Discontinuation due to side effects was far more common among women, who accounted for 90 percent of such cases, and among patients with higher baseline LDL cholesterol. In a multivariable regression model designed for small samples, age above 70 years nearly eight-fold increased the odds of discontinuation, while concomitant lipid-lowering therapy was strongly protective, cutting the odds by roughly 84 percent.

For context, the discontinuation rate compares favorably with older therapies. Real-world persistence data from a German insurance database covering about 77 percent of the outpatient prescription market show that at 36 months, only 20.6 percent of patients remained on statins, 22.3 percent on ezetimibe, and 50.9 percent on PCSK9 antibodies. Against that backdrop, roughly 72 percent persistence with a twice-yearly injection at three years is respectable, even if it falls short of the near-perfect adherence the dosing schedule was expected to deliver. Notably, nearly half of the patients who discontinued had previously been treated with PCSK9 antibodies, and in some cases therapy alternated between the two drug classes, suggesting that clinicians and patients were actively searching for the best fit in a difficult therapeutic landscape.

The safety findings will reassure the statin-intolerant, a group that has long had few options. Overall, 12.8 percent of patients reported adverse effects, most frequently muscle pain, followed by joint pain or swelling, injection-site reactions, and generalized pain. But among the 75 patients with statin intolerance, 86.7 percent experienced no adverse effects at all with inclisiran. This dissociation is biologically interesting, because statin-associated muscle symptoms are thought to involve mechanisms distinct from PCSK9 inhibition, and the result supports the idea that patients who cannot tolerate statins may still tolerate RNA-based lipid lowering well. It also strengthens the case for inclisiran as a cornerstone therapy for this population, alongside ezetimibe, PCSK9 antibodies, and the newer oral agent bempedoic acid.

The authors are candid about the limitations. The analysis was retrospective, lacked a control group, and drew on a highly selected cohort from specialized lipid clinics, limiting generalizability and introducing potential selection bias. Still, the study offers one of the clearest long-term pictures to date of how inclisiran performs outside the trial ecosystem, in exactly the complex, multi-intolerant patients for whom it was most needed. Its message is twofold. The drug works, often dramatically, and is tolerated by most statin-intolerant patients. But its real-world effect is variable, its durability uneven, and its persistence imperfect, underscoring that even a twice-yearly injection cannot replace individualized treatment strategies, careful monitoring over multiple timepoints, and honest conversations about what patients can expect from gene-silencing medicine in everyday care.

Subject of Research: Long-term real-world effectiveness and treatment persistence of the siRNA drug inclisiran for lowering LDL cholesterol

Article Title: Long-term LDL-C lowering and treatment persistence with inclisiran: 3-year follow-up from the German Inclisiran Network

Article References: Long-term LDL-C lowering and treatment persistence with inclisiran: 3-year follow-up from the German Inclisiran Network. (n.d.). https://doi.org/10.1007/s00392-026-03028-9

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03028-9

Keywords: inclisiran, LDL cholesterol, siRNA, PCSK9, statin intolerance, treatment persistence, familial hypercholesterolemia, cardiovascular risk, lipid clinics, real-world evidence, adherence, adverse effects